Post by Deb on Jun 18, 2005 10:06:25 GMT -5
In a move designed to cut costs, Biogen Idec Inc. of Cambridge yesterday said it would sell a new manufacturing plant in California to Genentech Inc. of South San Francisco.
The company had planned to use the plant to manufacture its multiple sclerosis drug Tysabri, which was pulled from the market in February after it was linked to a rare brain disease.
click here for more information>http://www.boston.com/business/articles/2005/06/17/to_cut_costs_biogen_to_sell_facility_for_408m/
The company had planned to use the plant to manufacture its multiple sclerosis drug Tysabri, which was pulled from the market in February after it was linked to a rare brain disease.
click here for more information>http://www.boston.com/business/articles/2005/06/17/to_cut_costs_biogen_to_sell_facility_for_408m/